György, Bence http://orcid.org/0000-0003-0766-6246
Nist-Lund, Carl
Pan, Bifeng http://orcid.org/0000-0001-9746-3420
Asai, Yukako
Karavitaki, K. Domenica
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Garcia, Sara P.
Zaborowski, Mikołaj P.
Solanes, Paola
Spataro, Sofia
Schneider, Bernard L. http://orcid.org/0000-0001-5485-8748
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
Géléoc, Gwenaëlle S. G.
Holt, Jeffrey R. http://orcid.org/0000-0002-7182-8011
Corey, David P. http://orcid.org/0000-0003-4497-6016
Article History
Received: 6 September 2018
Accepted: 24 May 2019
First Online: 3 July 2019
Competing interests
: J.R.H. holds patents on <i>TMC1</i> gene therapy and is an advisor to several biotech firms focused on inner-ear therapies. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals and Verve Therapeutics. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. holds equity in Excelsior Genomics, and is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.K.J. and B.P.K. are co-inventors on various patents and patent applications that describe gene editing and epigenetic editing technologies. The authors declare no other competing interests.